汉森制药(002412) - 2023 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2023 was ¥212,469,441.09, a decrease of 2.75% compared to the same period last year[4] - Net profit attributable to shareholders was ¥19,075,141.71, down 62.74% year-on-year[4] - The basic earnings per share (EPS) was ¥0.0379, reflecting a decline of 62.73% compared to the previous year[4] - Total operating revenue for the period reached CNY 684,141,818.56, a slight increase from CNY 681,150,652.08 in the previous period, representing a growth of approximately 0.29%[19] - Net profit for the period was CNY 109,742,317.45, down from CNY 130,074,008.87, reflecting a decline of approximately 15.6%[21] - Earnings per share (EPS) decreased to CNY 0.2181 from CNY 0.2585, indicating a decline of about 15.6%[21] Assets and Liabilities - Total assets at the end of the reporting period were ¥2,269,739,691.90, a decrease of 0.93% from the end of the previous year[4] - Total assets amounted to CNY 2,269,739,691.90, slightly down from CNY 2,290,944,050.05[18] - Total liabilities increased to CNY 405,548,766.63 from CNY 396,812,347.13, showing an increase of approximately 2%[18] - Total current assets as of September 30, 2023, amount to CNY 830,305,842.99, a decrease from CNY 865,402,215.15 at the beginning of the year[16] Cash Flow - Cash flow from operating activities for the year-to-date was ¥109,378,757.22, an increase of 9.74%[4] - The cash inflow from operating activities for the current period was CNY 784,850,845.91, an increase of 7.8% compared to CNY 727,909,881.30 in the previous period[22] - The net cash flow from operating activities was CNY 109,378,757.22, up from CNY 99,673,861.60, reflecting a growth of 7.1%[22] - Cash inflow from investment activities totaled CNY 795,118,314.05, significantly higher than CNY 105,725,650.98 in the previous period[22] - The net cash flow from investment activities was CNY 1,738,334.14, a recovery from a negative CNY 60,548,911.08 in the previous period[22] - Cash inflow from financing activities was CNY 103,094,444.48, down from CNY 151,504,745.40 in the previous period[23] - The net cash flow from financing activities was negative CNY 180,922,056.58, compared to a positive CNY 18,628,464.93 in the previous period[23] Shareholder Information - Total number of common shareholders at the end of the reporting period is 28,336[13] - Hainan Hansen Holdings holds 42.13% of the shares, making it the controlling shareholder[13] - The company has a total of 10 major shareholders, with the top 10 holding significant stakes[13] - The company does not have any preferred shareholders as per the report[14] Investment and Income - Investment income decreased by ¥26,522,813.57, a decline of 37.55% year-on-year, primarily due to reduced earnings from an associated company[8] - Other comprehensive income increased by 689.61% year-on-year, mainly due to improved earnings from an associated bank[9] - Other comprehensive income after tax was CNY 11,276,904.90, compared to a loss of CNY 1,912,591.42 in the previous period[21] Expenses - Total operating costs decreased to CNY 615,700,129.45 from CNY 622,255,079.62, marking a reduction of about 1.8%[19] - Research and development expenses were CNY 30,122,367.24, down from CNY 33,008,550.96, representing a decrease of approximately 8.6%[19] Cash and Equivalents - The company paid cash dividends of ¥150,960,000.00 during the reporting period, contributing to a 54.88% decrease in cash and cash equivalents[7] - Cash and cash equivalents decreased to CNY 65,600,648.70 from CNY 145,405,613.92[16] - The ending balance of cash and cash equivalents was CNY 65,600,648.70, a decrease from CNY 148,064,861.15 in the previous period[23]